ALOPECIA AREATA(AA)
Clinical trials for ALOPECIA AREATA(AA) explained in plain language.
Never miss a new study
Get alerted when new ALOPECIA AREATA(AA) trials appear
Sign up with your email to follow new studies for ALOPECIA AREATA(AA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New study to settle debate: which drug works best for Kids' hair loss?
Disease control Recruiting nowThis study compares two common drugs, cyclosporine and methotrexate, to treat moderate-to-severe alopecia areata in children aged 2-17. The goal is to see which medicine helps regrow hair better over 9 months. Participants and their parents choose which treatment to try, and doct…
Matched conditions: ALOPECIA AREATA(AA)
Phase: PHASE4 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug aims to regrow hair in alopecia patients
Disease control Recruiting nowThis early-stage study tests a new drug called HCW9302 in 30 adults with alopecia areata, a condition causing patchy or total hair loss. The drug is an IL-2 fusion protein given by injection. The main goal is to check safety and find the right dose for future studies, not to prov…
Matched conditions: ALOPECIA AREATA(AA)
Phase: PHASE1 • Sponsor: HCW Biologics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New injection aims to regrow hair in patchy baldness
Symptom relief Recruiting nowThis early-stage study tests whether ALD-102, a solution injected into the scalp, is safe and can help regrow hair in people with alopecia areata. About 24 adults aged 18-55 will receive either the drug, a placebo (saline), or no treatment in different scalp areas. The main goal …
Matched conditions: ALOPECIA AREATA(AA)
Phase: PHASE1, PHASE2 • Sponsor: Aldena Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Blood test may reveal hidden clues to hair loss severity
Knowledge-focused Recruiting nowThis study investigates whether two substances in the blood—GPX4 and MDA—are linked to the severity of alopecia areata, a condition that causes patchy hair loss. Researchers will compare levels of these markers in 104 people with alopecia areata and 52 healthy volunteers. The goa…
Matched conditions: ALOPECIA AREATA(AA)
Sponsor: Istanbul Training and Research Hospital • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC